In:
The Journal of Immunology, The American Association of Immunologists, Vol. 186, No. 1_Supplement ( 2011-04-01), p. 67.9-67.9
Abstract:
Dengue virus infection is a major public health problem in tropical and subtropical countries. Around 50 million people are infected per year of which 500,000 cases develop into the severe form, dengue hemorrhagic fever (DHF). Dengue is a flavivirus circulating as 4 serotypes with an average of 30% amino acid difference between each other, and infection with one serotype dose not provide protective immunity to the others, so secondary infection is very common. So far, the mechanisms involved in the pathogenesis of DHF are not well understood, but the key epidemiological studies indicate that it usually occurs in subsequent heterotypic dengue infection. Antibody dependent enhancement (ADE) is one of the hypotheses where preexisting antibodies from primary infection may be unable to neutralise other serotype from secondary infection but may instead form dengue/antibody complexes which will be taken up by Fc-bearing cells such as monocytes and macrophages leading to increase viral production. In this study, we have generated a panel of human monoclonal antibodies against dengue virus from B cells isolated from dengue infected patients. Neutralizing, enhancing and cross-reactive activity of these antibodies have been characterized and shown different patterns of functioanl properties.
Type of Medium:
Online Resource
ISSN:
0022-1767
,
1550-6606
DOI:
10.4049/jimmunol.186.Supp.67.9
Language:
English
Publisher:
The American Association of Immunologists
Publication Date:
2011
detail.hit.zdb_id:
1475085-5
